Renal Dosing Adjustments for Patients with eGFR 50 mL/min/1.73 m²

General Principles for Renal Dosing

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines strongly recommend that prescribers take GFR into account when dosing medications, with a Grade 1A recommendation, for patients with moderate chronic kidney disease (CKD G3a) 2, 3
• At eGFR 50 mL/min/1.73 m², patients fall into CKD category G3a, which triggers dosing considerations for renally cleared drugs and nephrotoxic agents, according to the American Journal of Kidney Diseases 1, 2

Medication Classes Requiring Adjustment

• Aminoglycosides, such as gentamicin, require dose reduction and/or increased dosing interval when GFR <60 mL/min/1.73 m², with mandatory monitoring of serum trough and peak levels, as recommended by the American Journal of Kidney Diseases 1
• Tetracyclines require dose reduction when GFR <45 mL/min/1.73 m² and can exacerbate uremia, according to the American Journal of Kidney Diseases 1
• Antifungals, such as fluconazole, require dose reduction by 50% when GFR <45 mL/min/1.73 m², and flucytosine requires dose reduction when GFR <60 mL/min/1.73 m², as recommended by the American Journal of Kidney Diseases 1
• NSAIDs should be avoided entirely when GFR <30 mL/min/1.73 m² and prolonged therapy is not recommended in patients with GFR <60 mL/min/1.73 m², according to the American Journal of Kidney Diseases 1
• Opioids require dose reduction when GFR <60 mL/min/1.73 m² due to accumulation of active metabolites and increased risk of adverse effects, as recommended by the American Journal of Kidney Diseases 1
• RAAS antagonists, such as ACE inhibitors, ARBs, and aldosterone antagonists, should be started at lower doses when GFR <45 mL/min/1.73 m², with assessment of GFR and potassium within 1 week of starting or dose escalation, and temporarily suspended during intercurrent illness, according to the American Journal of Kidney Diseases 1, 2
• Digoxin requires dose reduction based on plasma concentrations due to reduced renal clearance, as recommended by the American Journal of Kidney Diseases 1
• Metformin can be continued safely at eGFR 50 mL/min/1.73 m², but use should be reviewed when GFR falls to 30-44 mL/min/1.73 m² and discontinued when GFR <30 mL/min/1.73 m², according to the American Journal of Kidney Diseases 2, 3
• Sulfonylureas, such as gliclazide, may need reduced doses when GFR <30 mL/min/1.73 m², and renally excreted agents like glyburide should be avoided, as recommended by the American Journal of Kidney Diseases 1
• Low-molecular-weight heparins require dose reduction when GFR <30 mL/min/1.73 m², but at eGFR 50, standard dosing is generally appropriate with monitoring, according to the American Journal of Kidney Diseases 1

Important Considerations for eGFR Calculation and Medication Review

• The Cockcroft-Gault equation or direct measurement may be preferred for drugs with narrow therapeutic indices where precision is required, as recommended by the American Journal of Kidney Diseases 2
• Patients should be monitored closely for adverse effects, and therapeutic drug monitoring should be considered for medications with narrow therapeutic windows, such as aminoglycosides, digoxin, and lithium, according to the American Journal of Kidney Diseases 1, 2
• Potentially nephrotoxic and renally excreted drugs should be temporarily discontinued during intercurrent illness, contrast administration, or bowel preparation, as recommended by the American Journal of Kidney Diseases 2, 3